VAREX IMAGING CORP

Company Overview

Varex Imaging Corporation designs and manufactures X‑ray imaging components and subsystems for medical modalities (CT, fluoroscopy, radiography) and select industrial applications. In Q3 FY2025 the company reported $203.0M of revenue (down 2.9% year‑over‑year) with nine‑month revenue up 1.7% to $615.7M; gross margin improved to 33.3% and backlog was about $284M while DSO improved to 61 days. Management cites regional variability (notably an APAC decline driven by lower X‑ray tube sales), replacement/service demand dynamics, and ongoing tariff/trade risks (including a paused MOFCOM investigation) as near‑term uncertainties. The quarter included a $93.9M non‑cash goodwill impairment tied to the Medical reporting unit, R&D spending steady at ~10–11% of revenue, and net debt of about $367.5M with available revolver capacity.

Executive Compensation Practices

Given Varex’s business model and recent filings, incentive pay is likely to emphasize metrics that management can influence directly: revenue and regional sales (especially APAC CT replacement cycles), gross margin improvement from medical productivity gains, free cash flow / operating cash flow and working capital conversion (DSO/backlog turnover), and leverage reduction given recent debt activity. Long‑term equity awards are likely to be RSUs/PSUs tied to multi‑year EBITDA/gross‑margin targets, cash conversion or net debt/EBITDA goals, and possibly product development or reliability/quality milestones reflecting the company’s manufacturing focus. The $93.9M goodwill impairment and tariff/geo‑political risks increase the chance of performance targets being adjusted or supplemented by retention grants, and may lead the board to weight cash/credit metrics more heavily to incentivize deleveraging and liquidity preservation.

Insider Trading Considerations

Insider trades at Varex should be watched around a few company‑specific triggers: earnings releases and guidance (backlog conversion and regional demand), updates on MOFCOM/tariff matters, debt financings or repayments (convertible note actions), and material goodwill or impairment disclosures. Expect routine trading governance—blackout windows around financial reporting and material events, and likely use of 10b5‑1 plans for planned sales—so clustered or opportunistic sales immediately after favorable guidance or clearance of regulatory risk are common signals. Given the recent impairment and ongoing trade risks, insider purchases would be a higher‑conviction bullish signal, whereas sales following equity vesting or option exercises are more likely administrative; monitor Form 4 timing relative to RSU vesting, debt events and material regulatory developments for actionable patterns.